NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $19.83 0.00 (0.00%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$20.07 +0.24 (+1.21%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About NewAmsterdam Pharma Stock (NASDAQ:NAMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$19.71▼$20.6750-Day Range$19.83▼$28.5352-Week Range$19.58▼$42.21Volume1.94 million shsAverage Volume1.69 million shsMarket Capitalization$2.37 billionP/E RatioN/ADividend YieldN/APrice Target$48.90Consensus RatingModerate Buy Company Overview NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company’s lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities. Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia. NewAmsterdam has conducted late-stage clinical trials, including the BROADWAY and BROOKLYN studies, to evaluate the product’s efficacy and safety. As a clinical-stage company, NewAmsterdam does not yet have an approved commercial product. NewAmsterdam Pharma was established through the combination of businesses involved in the development of obicetrapib and became publicly traded on the Nasdaq under the symbol NAMS following a business combination with Frazier Lifesciences Acquisition Corporation in 2022. The company is led by Chief Executive Officer Michael Davidson, M.D., and conducts its clinical development activities across international markets.AI Generated. May Contain Errors. Read More NewAmsterdam Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreNAMS MarketRank™: 2.912685774945 of 5 starsNewAmsterdam Pharma scored higher than 58% of companies evaluated by MarketBeat, and ranked 272nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingNewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNewAmsterdam Pharma has a consensus price target of $48.90, representing about 146.6% upside from its current price of $19.83.Amount of Analyst CoverageNewAmsterdam Pharma has only been the subject of 3 research reports in the past 90 days.Read more about NewAmsterdam Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.82) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NewAmsterdam Pharma is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewAmsterdam Pharma is -9.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NewAmsterdam Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.26% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 9.39.Change versus previous monthShort interest in NewAmsterdam Pharma has recently increased by 21.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment-0.33 News SentimentNewAmsterdam Pharma has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NewAmsterdam Pharma this week, compared to 4 articles on an average week.Search Interest5 people have searched for NAMS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows8 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership2.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 3,364.73% more of their company's stock than they have bought. Specifically, they have bought $226,500.00 in company stock and sold $7,847,619.00 in company stock.Percentage Held by Insiders12.74% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAMS Stock News HeadlinesDoes NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?October 14, 2026 | finance.yahoo.comRBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative RiskOctober 5, 2026 | marketscreener.comMDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 19 at 1:00 AM | Stansberry Research (Ad)NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 50,246 Shares of StockOctober 3, 2026 | insidertrades.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comNewAmsterdam Pharma: Can Obicetrapib's Data In Diabetes And Metabolic Syndrome Bring Back The Mojo?September 30, 2026 | rttnews.comNewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's DiseaseSeptember 29, 2026 | finance.yahoo.comNewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s DiseaseSeptember 29, 2026 | markets.businessinsider.comSee More Headlines NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $35.08 at the start of the year. Since then, NAMS shares have decreased by 43.5% and is now trading at $19.83. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.04. The business earned $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative trailing twelve-month return on equity of 34.81%. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NewAmsterdam Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Advanced Micro Devices (AMD), Novo Nordisk A/S (NVO), Oklo (OKLO), Uranium Energy (UEC), AST SpaceMobile (ASTS), Micron Technology (MU) and NVIDIA (NVDA). Company Calendar Last Earnings8/05/2026Today10/19/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NAMS's financial health is in the Red zone, according to TradeSmith. NAMS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NAMS CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees100Year Founded2019Price Target and Rating Average Price Target for NewAmsterdam Pharma$48.90 High Price Target$58.00 Low Price Target$37.00 Potential Upside/Downside+146.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$203.82 million Net Margins-3,644.21% Pretax Margin-3,644.21% Return on Equity-34.81% Return on Assets-31.50% Debt Debt-to-Equity RatioN/A Current Ratio9.03 Quick Ratio9.03 Sales & Book Value Annual Sales$7.12 million Price / Sales332.88 Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book3.32Miscellaneous Outstanding Shares119,537,000Free Float104,308,000Market Cap$2.37 billion OptionableOptionable Beta0.10 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NAMS) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
